Skip to main content

BeneFIX 250 Int'l Units Disease Interactions

There are 2 disease interactions with BeneFIX 250 Int'l Units (coagulation factor ix).

Major

Prothrombin complex (applies to BeneFIX 250 Int'l Units) heparin-induced thrombocytopenia

Major Potential Hazard, Moderate plausibility.

The brand name products, Kcentra and Bebulin of prothrombin complex, contain heparin; therefore, their use is contraindicated in patients with known heparin-induced thrombocytopenia.

References

  1. "Product Information. Kcentra (prothrombin complex)." CSL Behring LLC (2013):
Major

Prothrombin complex (applies to BeneFIX 250 Int'l Units) thromboembolism

Major Potential Hazard, Moderate plausibility. Applicable conditions: Coagulation Defect, Thrombotic/Thromboembolic Disorder, Thrombotic Thrombocytopenic Purpura, Myocardial Infarction, Pulmonary Embolism, Disseminated Intravascular Coagulation

The brand name product, Kcentra of prothrombin complex is contraindicated in patients with disseminated intravascular coagulation (DIC). Both fatal and non-fatal arterial thromboembolic events (including acute myocardial infarction and arterial thrombosis), and venous thromboembolic events (including pulmonary embolism and venous thrombosis) and disseminated intravascular coagulation have been reported with the use of this product in clinical trials and post marketing surveillance. Exercise care if using this product in patients with a history of thromboembolic events.

References

  1. "Product Information. Kcentra (prothrombin complex)." CSL Behring LLC (2013):

BeneFIX 250 Int'l Units drug interactions

There are 5 drug interactions with BeneFIX 250 Int'l Units (coagulation factor ix).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer